BUZZ - Brokerage opinion: Pepsi's growth strategy in the US still needs adjustment
路透社2026/10/09 10:00October 9 - Snack and soft drink giant PepsiCo (PEP.O) warned on Thursday that the recovery of growth and profit margins in its key North American market will take longer than planned, and stated it will implement further cost-cutting measures to offset weak demand for its snacks and beverages. Twenty-five analysts have given the stock an average rating of "Hold," with a median target price of $145, according to data compiled by LSEG. JPMorgan (rating: "Neutral," target price: $137) pointed out that the company remains strong in international markets, but demand for snacks and beverages in North America remains weak, with limited signs of near-term improvement. Deutsche Bank (rating: "Hold," target price: $132) noted that PepsiCo's North American Beverages (PBNA) segment continues to lag the competition, with weak profit margins. Although the company plans to strengthen brand investment and execution, the path to sustained improvement remains unclear. Piper Sandler ("Overweight," target price: $140) indicated that the company faces weak U.S. demand and cost pressures. While new protein and hydration products may support growth, such prospects have yet to be validated. RBC Capital Markets ("Sector Perform," target price: $150) highlighted that North American beverages remain the main drag, while franchise re-authorization could support longer-term growth.
October 9 - ** Snack and soft drink giant PepsiCo (PEP.O) warned on Thursday that growth and profit margin recovery (link) in its key North American market will take longer than planned, and said it would implement further cost-cutting measures to offset sluggish demand for its snacks and beverages.
** The average rating of the stock by 25 analysts is "Hold"; median target price is $145 — data compiled by LSEG.
Seeking answers
** JPMorgan ("Neutral" rating, target price: $137) noted that the company's international markets remain strong, but demand for snacks and beverages in North America remains weak, with limited signs of improvement in the short term.
** Deutsche Bank ("Hold" rating, target price: $132) pointed out that PepsiCo's North America Beverages (PBNA) business remains at a competitive disadvantage and has weak profit margins; although the company plans to intensify brand investment and execution, the path to sustainable improvement is still unclear.
** Piper Sandler ("Overweight," target price: $140) highlighted that the company faces weak U.S. demand and cost pressures; although newly launched protein and hydration products may support growth, the growth outlook is yet to be validated.
** RBC Capital Markets ("Sector Perform," target price: $150) said the company's North America beverages business remains the main drag, while franchise re-authorization may help boost long-term growth.
(To facilitate non-native English speakers, Reuters provides automated translations of its reports into several other languages. Due to the potential for errors or lack of required context in automated translations, Reuters does not guarantee the accuracy of the automated translation and provides it solely for the convenience of readers. Reuters accepts no liability for any damage or loss arising from the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Moderna stock surges after inclusion in Nasdaq 100 index; Bank of America raises target price
On October 9, Moderna (MRNA.O) shares rose by about 12% to $220 on Friday, after reaching their highest point since January 2022, as the company was added to the Nasdaq 100 Index (.NDX). Bank of America raised its price target for the stock from $170 to $200. On Thursday, the stock closed at $197. Bank of America analysts maintained a neutral rating and noted that the price target was raised due to a slight reduction in expectations for U.S. COVID-related revenues, offset by anticipated growth in influenza sales by 2027. This also factored in an increase in the expected price for intismeran, as well as projected sales growth for the drug in the coming years; intismeran is a cancer vaccine co-developed with Merck (MRK.N). However, they pointed out that much of intismeran's value has already been reflected in the share price ahead of the European Society for Medical Oncology (ESMO) conference and upcoming data releases. Since the third-quarter earnings report will only be announced after the presentation at the ESMO conference on October 24, Bank of America noted that the significance of the Q3 results is relatively low. Nevertheless, BofA still expects the company to achieve its guidance of up to 10% revenue growth for 2026, with year-end cash holdings reaching $4.7 billion to $5.2 billion. The bank also stated its forecast for third-quarter preventive vaccine revenue is $812 million, below market consensus, and its total revenue estimate of $848 million is likewise below consensus. Since August 18, Moderna's stock price has been on a strong uptrend, following encouraging late-stage clinical data on intismeran, which encouraged investors to buy the stock. Moderna was included in the Nasdaq 100 Index (link), replacing Warner Bros. Discovery, which is set to merge with Paramount Global. Year-to-date, Moderna shares are up about 650%, marking the largest annual gain in its history, making it the top performer in the S&P 500 Index (.SPX) year-to-date. In contrast, the S&P 500 Healthcare Index (.SPXHC) is up only 10.3% so far in 2026. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several other languages. As automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of automated translated texts, and these are provided solely for the reader's convenience. Reuters assumes no responsibility for any damage or losses caused by the use of automated translation functionality.)
Update: Equities Rise Intraday as Traders Parse Consumer Sentiment Survey
01:37 PM EDT, 10/09/2026 (MT Newswires) -- (Updates with latest market prices and developments.) US benchmark equity indexes were higher intraday as investors evaluated a survey on consumer sentiment. The Dow Jones Industrial Average was up 0.8% at 51,628.8 after midday Friday, while the Nasdaq Composite and the S&P 500 rose 0.6% each to 27,352.4 and 7,809.5, respectively. Barring communication services, all sectors were in the green, led by real estate. US consumer sentiment fell in October as the one- and five-year inflation expectations reached their highest levels since May, preliminary results of a University of Michigan survey showed Friday. "While year-ahead expectations for personal finances and business conditions crept up slightly, buying conditions for durables plummeted amid high prices and borrowing costs," Surveys of Consumers Director Joanne Hsu said. "Frustration over cost-of-living continues to mount, as consumers across the political spectrum believe that the trajectory of the economy has weakened since the beginning of the year." Markets are currently pricing in a nearly 81% probability that the Federal Reserve will keep its benchmark rate steady later this month, with the remaining odds in favor of a second consecutive 25-basis-point hike, as the central bank looks to tame inflation, according to the CME FedWatch tool. West Texas Intermediate crude was down 0.4% at $91.17 a barrel intraday, while Brent lost 0.5% to $103.81. The 10-year US Treasury yield was up 1.5 basis points at 5.25%, while the two-year rate increased 3.9 basis points to 4.8%. In company news, SpaceX (SPCX) shares were up 0.5%. The rocket and satellite company said late Thursday it agreed to acquire a nationwide low-band spectrum portfolio from investment firm Grain Management as it seeks to establish Starlink Mobile as a major US mobile carrier. T-Mobile US (TMUS) shares sank 13% intraday Friday, the worst performer on the S&P 500, followed by AT&T (T) and Verizon Communications (VZ), which fell 10% and 9.8%, respectively.
Ameren declares quarterly dividend of $0.75 a share
Ameren declared a quarterly cash dividend of 75 cents per common share. Dividend payable Dec. 31, 2026. Shareholders of record as of Dec. 8, 2026 will receive the dividend. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ameren Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610091331PR_NEWS_USPR_____CG68019) on October 09, 2026, and is solely responsible for the information contained therein.
McEwen’s $55M Ontario asset sale fuels gold growth plans